ADMA Biologics (ADMA) Price & Analysis

Compare

2,929 Followers

ADMA Stock Chart & Stats

Day’s Range― - ―

52-Week Range$13.50 - $25.67

Previous CloseN/A

Volume407.39K

Average Volume (3M)2.94M

Market Cap

$4.00B

Enterprise Value$4.52B

Total Cash (Recent Filing)$90.28M

Total Debt (Recent Filing)$83.83M

Price to Earnings (P/E)20.3

Beta0.97

Next Earnings

Nov 05, 2025

EPS Estimate

0.15

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)0.15

Shares Outstanding238,630,720

10 Day Avg. Volume4,327,874

30 Day Avg. Volume2,941,826

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap1.13

Enterprise Value/Revenue9.53

Enterprise Value/Gross Profit17.99

Enterprise Value/Ebitda27.72

Forecast

1Y Price Target

$19.50

Price Target Upside14.91% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

Bulls Say, Bears Say

Bulls Say

Production ExpansionExpansion of collection centers from 50-70 to over 250 increases raw plasma acquisition capabilities.

Supply ChainLong-term plasma supply agreements have set the stage for achieving over $1 billion in sales by 2030.

Bears Say

Filing DelayADMA stated it would be unable to file its 2024 10-K within the prescribed timeframe.

Filing UncertaintyThe filing of ADMA's 10-K is seen as a clearing event, resolving previous accounting concerns and shifting focus to the expansion of ASCENIV.

ADMA Biologics News

Closing Bell Movers: DoorDash jumps 8%, Airbnb slips 6% on earnings

In the opening 90 minutes of the evening session, U.S. equity futures are up slightly – S&P 500...

9d ago

ELF

MCK

Adma Biologics reports Q2 EPS 14c, consensus 14c

Reports Q2 revenue $121,98M, consensus $121.77M. The company said, “”The second quarter was another highly productive period for...

9d ago

ADMA

Adma Biologics affirms 2025 revenue outlook over $500M, consensus $505.83M

The company said, “Potential upside from the FDA-approved yield enhancement process remains excluded from 2025 guidance and is...

9d ago

ADMA

Adma Biologics sees 2026 revenue $625M or more, consensus $637.28M

16:18 EDT Adma Biologics (ADMA) sees 2026 revenue $625M or more, consensus $637.28M Published first on TheFly –...

9d ago

ADMA

ADMA Biologics Earnings Call Highlights Robust Growth

ADMA Biologics Inc (($ADMA)) has held its Q2 earnings call. Read on for the main highlights of the...

8d ago

ADMA

ADMA Biologics Reports Strong Q2 2025 Results

ADMA Biologics Inc ( ($ADMA) ) has released its Q2 earnings. Here is a breakdown of the information...

9d ago

ADMA

ADMA Biologics Secures $300M Credit Agreement with JPMorgan

ADMA Biologics ( ($ADMA) ) has provided an update. On August 5, 2025, ADMA Biologics entered into a...

9d ago

ADMA

ADMA Biologics Inc. Warns Investors of Significant Business Risks in Latest Report

ADMA Biologics Inc (ADMA) has disclosed a new risk, in the Regulation category. ADMA Biologics Inc. faces significant...

15d ago

ADMA

Insider Sales Shake Up Phillips 66, Bloom Energy, Transocean, Mullen Automotive, and ADMA Biologics

Insiders have been trading these 5 stocks: (($PSX)), (($BE)), (($RIG)), (($MULN)) and (($ADMA)). Here is a breakdown of...

2M ago

PSX

ADMA Biologics Holds Annual Stockholders Meeting

ADMA Biologics ( ($ADMA) ) has issued an update. On June 4, 2025, ADMA Biologics, Inc. held its...

2M ago

ADMA

ADMA Biologics Reports Strong Growth and Strategic Advances

ADMA Biologics Inc (($ADMA)) has held its Q1 earnings call. Read on for the main highlights of the...

3M ago

ADMA

Adma Biologics price target raised to $32 from $25 at Raymond James

Raymond James raised the firm’s price target on Adma Biologics (ADMA) to $32 from $25 and keeps a...

3M ago

ADMA

ADMA Biologics Reports Strong Q1 2025 Financial Growth

ADMA Biologics Inc ( ($ADMA) ) has released its Q1 earnings. Here is a breakdown of the information...

3M ago

ADMA

ADMA Biologics Announces $500M Share Repurchase Program

The latest update is out from ADMA Biologics ( ($ADMA) ). In the first quarter of 2025, ADMA...

3M ago

ADMA

ADMA FAQ

What was ADMA Biologics’s price range in the past 12 months?

ADMA Biologics lowest stock price was $13.50 and its highest was $25.67 in the past 12 months.

What is ADMA Biologics’s market cap?

ADMA Biologics’s market cap is $4.00B.

When is ADMA Biologics’s upcoming earnings report date?

ADMA Biologics’s upcoming earnings report date is Nov 05, 2025 which is in 82 days.

How were ADMA Biologics’s earnings last quarter?

ADMA Biologics released its earnings results on Aug 06, 2025. The company reported $0.147 earnings per share for the quarter, beating the consensus estimate of $0.137 by $0.01.

Is ADMA Biologics overvalued?

According to Wall Street analysts ADMA Biologics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does ADMA Biologics pay dividends?

ADMA Biologics does not currently pay dividends.

What is ADMA Biologics’s EPS estimate?

ADMA Biologics’s EPS estimate is 0.15.

How many shares outstanding does ADMA Biologics have?

ADMA Biologics has 238,630,720 shares outstanding.

What happened to ADMA Biologics’s price movement after its last earnings report?

ADMA Biologics reported an EPS of $0.147 in its last earnings report, beating expectations of $0.137. Following the earnings report the stock price went down -9.655%.

Which hedge fund is a major shareholder of ADMA Biologics?

Currently, no hedge funds are holding shares in ADMA

ADMA Biologics Stock Smart Score

Neutral

Fundamentals

Return on Equity

71.23%

Trailing 12-Months

Asset Growth

48.35%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

ADMA Biologics

ADMA Biologics, Inc. is a biopharmaceutical company focused on the development and commercialization of specialty pharmaceutical products for the treatment and prevention of infectious diseases. The company operates primarily in the sector of immunoglobulin therapies, leveraging its proprietary manufacturing processes to produce high-quality immunoglobulin products derived from human plasma. ADMA's core products include its lead product, ASCENIV, an immunoglobulin product used for the treatment of primary immunodeficiency, as well as other specialty products aimed at addressing unmet medical needs in the healthcare market.

ADMA Biologics (ADMA) Earnings & Revenues

Historic Earnings Reports

ADMA Earnings Call

Q2 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call reflects a strong performance by ADMA Biologics with significant revenue growth, successful strategic initiatives, and promising advancements in R&D. While there are challenges related to growth guidance and payer dynamics, the positive developments in yield enhancement, market penetration, and infrastructure expansion outweigh these concerns.View all ADMA earnings summaries

ADMA Stock 12 Month Forecast

Average Price Target

$19.50

▲(14.91% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"8":"$8","12":"$12","16":"$16","20":"$20","24":"$24"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":19.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$19.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":19.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$19.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":19.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$19.50</span>\n  </div></div>","useHTML":true}}],"tickPositions":[8,12,16,20,24],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,19.33,19.34307692307692,19.356153846153845,19.369230769230768,19.38230769230769,19.395384615384614,19.408461538461538,19.42153846153846,19.434615384615384,19.447692307692307,19.46076923076923,19.473846153846154,19.486923076923077,{"y":19.5,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,19.33,19.34307692307692,19.356153846153845,19.369230769230768,19.38230769230769,19.395384615384614,19.408461538461538,19.42153846153846,19.434615384615384,19.447692307692307,19.46076923076923,19.473846153846154,19.486923076923077,{"y":19.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,19.33,19.34307692307692,19.356153846153845,19.369230769230768,19.38230769230769,19.395384615384614,19.408461538461538,19.42153846153846,19.434615384615384,19.447692307692307,19.46076923076923,19.473846153846154,19.486923076923077,{"y":19.5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":9.55,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.55,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.26,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.77,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.37,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.69,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.15,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.39,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.42,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.27,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.43,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.88,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.33,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >